The study warns that failure to act risks normalizing a creative economy defined by exploitation, invisibility, and ...

Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with ...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three ...

Q2 2026 Earnings Call Transcript November 10, 2025 Beyond Air, Inc. misses on earnings expectations. Reported EPS is $-1.25 ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including ...

The near-term outlook for ClearPoint's biopharma business is also now clouded by FDA uncertainty around uniQure's AMT-130.

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...

BrainsWay's growth remains strong, and its margins are improving as the business scales. This situation appears set to ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings, and welcome to the HeartBeam Third Quarter 2025 ...

Operator: Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited ...